Day-Storms, LLC’s Post

🔬 Latest CPT® PLA Code Updates: Key Insights for Healthcare Professionals 🔬 Excited to share our newsletter focused on the recent CPT® Proprietary Laboratory Analyses (PLA) Codes updates by the AMA. This concise guide is designed for those at the cutting edge of medical diagnostics, offering: 🔸Insights into Personalized Medicine & Oncology advancements. 🔸Highlights on Advanced Diagnostic Techniques and their impact. 🔸Updates on Infectious Diseases management and the fight against antibiotic resistance. 🔸Exploration of the Expanding Scope of medical diagnostics. 📄 Why Read? Stay informed about crucial coding updates that affect patient care, healthcare delivery, and diagnostics. Perfect for healthcare professionals and laboratory scientists keen on leveraging the latest in medical diagnostics for enhanced patient outcomes. #HealthcareInnovation #CPTUpdates #PrecisionMedicine #Oncology #InfectiousDiseases #MedicalWriting

🤝 𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐓𝐡𝐫𝐨𝐮𝐠𝐡 𝐈𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬🤝 Research on patient decision aids (PDAs) clearly benefits adults facing healthcare choices. (https://rb.gy/knbids) The article's highlights: 🎯 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐊𝐧𝐨𝐰𝐥𝐞𝐝𝐠𝐞 & 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬: Adults using PDAs demonstrated significant gains in understanding their options. ● 𝐑𝐞𝐚𝐥𝐢𝐬𝐭𝐢𝐜 𝐄𝐱𝐩𝐞𝐜𝐭𝐚𝐭𝐢𝐨𝐧𝐬: PDAs helped patients develop clear expectations of each option's benefits and potential drawbacks. ● 𝐀𝐜𝐭𝐢𝐯𝐞 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐢𝐨𝐧: Patients using PDAs reported feeling more involved and engaged in decision-making. 😊 𝐈𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐂𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞: There was a strong association between PDAs and patients feeling better equipped and informed. ● 𝐕𝐚𝐥𝐮𝐞𝐬-𝐃𝐫𝐢𝐯𝐞𝐧 𝐂𝐡𝐨𝐢𝐜𝐞𝐬: PDAs empowered patients to identify their priorities and make choices aligned with what matters most. ● 𝐑𝐞𝐝𝐮𝐜𝐞𝐝 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐑𝐞𝐠𝐫𝐞𝐭: Importantly, our research found no evidence of increased decision regret among patients who used PDAs. ✔ These findings strongly suggest that PDAs are valuable for promoting shared decision-making between patients and healthcare providers. In WP3, physicians and patients are currently sharing their points of view for shared decision-making in ovarian cancer cases. 🚀 More information can be found here: https://lnkd.in/epjAqhCa

Live updates from the prestigious AD/PD - Advances in Science & Therapy Conference in Lisbon! 🎉  What an inspiring day here at AD/PD™ 2024! Noselab's groundbreaking diagnostic platform is now unveiled.   So many leading international experts are joining us in celebrating a major milestone in #Alzheimer's disease (AD) diagnostic! At #ADPD2024 we share insights, discuss clinical trials, and unveil novel therapeutic approaches.  Our proprietary diagnostic platform marks a significant leap forward in early detection and patient care. By harnessing nasal biomarkers at the brain-nose interface (BNI), our platform offers an alternative to conventional methods like PET scans and CSF analysis. Through detailed quantification of AD biomarkers in nasal cerebrospinal fluid (#nCSF), we're empowering clinicians with valuable insights for early-stage screenings, patient stratification, and treatment monitoring. As we continue our journey to innovate and redefine neurodegenerative disease diagnostics, we invite you to join us in shaping the future of healthcare.   #AlzheimersResearch #InnovationInHealthcare #MedicalBreakthroughs 

In this Medical Product Outsourcing op-ed by Dr. Jeff Andrews, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD Life Sciences, notes that unfortunately, the U.S. has fallen behind countries like Denmark, Sweden, the Netherlands, Kenya, Australia and New Zealand, just to name a few, where women are empowered to self-collect for cervical cancer screening. (The FDA has not yet approved self-collection tests for cervical cancer screening in the US). Equally viable and effective, self-collection solutions allow women to collect their own samples without clinician assistance, and in some cases, from the privacy of their homes, foregoing not only the inconvenience but also the added expenses and discomfort often associated with in-person pelvic exams. Self-collection is less invasive. It does not require stirrups and a speculum – just a small swab. The more women can get screened, the more we can detect precancer early and prevent cervical cancer. Let’s work together to address the lack of access to health care that persists around the world. #CervicalCancerAwarenessMonth #SelfCollection #CervicalCancerPrevention #EquitableHealthCare #BDemployee

Day One is pleased to share our recently published descriptive cross-sectional pilot study in Neuro-Oncology Practice, which characterized the disease profile, treatment, and healthcare utilization in pediatric low-grade glioma (pLGG), a relentless, chronic cancer that has a high overall survival rate but is associated with life-long disease- and treatment-related morbidity. By looking beyond single-institution experience, this retrospective study of linked claims and electronic health records (Optum® Market Clarity Data) explored the feasibility of quantifying disease burden and healthcare resource utilization in a cohort of patients with pLGG. Read more: https://bit.ly/3UEoH7G

For patients with newly diagnosed multiple myeloma (NDMM), the development of novel therapies and combinations in recent years has provided numerous therapeutic options. However, selecting optimal induction therapy and treatment sequencing remains a challenge. Join Dr. Gurbakhash Kaur, Assistant Professor of Internal Medicine at the University of Texas Southwestern Medical Center, for an expert discussion on treatment combination and sequencing strategies recommended by current guidelines, the mechanisms of action and efficacy of anti-CD38 monoclonal antibodies, the roles of measurable residual disease (MRD) assessment in treatment, monitoring and managing toxicities associated with novel therapies, and strategies for optimizing survivorship care. 🔗 Register now to stay updated with the latest in NDMM treatment: https://bit.ly/3yxlqim #MultipleMyeloma #MedicalEducation #HealthcareProfessionals

Though there has been increased interest in using patient-reported outcomes, or PROs, as part of routine cancer care, barriers at the patient, clinician, and administrative levels have limited their implementation. Patient buy-in requires asking relevant and clinically useful questions, being sensitive to patient burden, and providing accessible options for PRO measure completion. Clinicians also experience their own barriers to PRO use. Traditional workflows require modifications to integrate PROs with clinic notes, laboratory results, and imaging findings. Workflows must present PRO data so that clinic discussions can focus on patients’ most relevant issues and support documentation requirements. As a result of these barriers, there is no one-size-fits-all PRO system. Each system must be adapted to the intended goals and resources available. For ASCO Daily News, a new expert editorial examines the potential for PRO use and the challenges involved: https://brnw.ch/21wKIXL

Early diagnosis, increased awareness and effective therapies have improved outcomes of patients with AL amyloidosis. Future should focus on unmet clinical needs, development of patient centric clinical trials with PROs as endpoints and by engaging and collaboration with all stakeholders. #amyloidosis #raredisease

ICD-11 was specifically designed for the following use cases:  Certification and reporting of causes of death Morbidity coding and reporting including primary care Casemix and Diagnosis-Related Grouping (DRG) Assessing and monitoring the safety, efficacy, and quality of care Cancer registries  Antimicrobial resistance (AMR) Researching and performing clinical trials and epidemiological studies Assessing functioning  Coding traditional medicine conditions Interoperability standard in WHO Digital Guidelines and for Digital Documentation of COVID-19 Certificates (DDCC) Clinical documentation

From Misdiagnosis to Precision: How expert consultation changed the treatment plan for Pheochromocytoma? The patient initially received a pathological diagnosis of Paraganglioma, for which the preferred treatment outside of a clinical trial was a chemotherapy regimen including Cytoxan, Vincristine, and DTIC. However, understanding the critical need for precise diagnosis in guiding effective treatment, we facilitated an expert pathological consultation through Arbuda. This review resulted in a revised diagnosis to Pheochromocytoma—a related but biologically distinct tumor that presents different challenges and management strategies compared to Paraganglioma. Given the new diagnosis, the treatment strategy was significantly altered. Instead of continuing with chemotherapy, the patient was started on Beta-Blockers to manage the symptoms effectively associated with Pheochromocytoma, such as hypertension and rapid heart rate. Additionally, we planned for radiation therapy as a targeted approach to control the tumor growth, aligning the treatment more closely with the specific biology of Pheochromocytoma and aiming to improve the patient’s overall prognosis. This shift in diagnosis and subsequent change in the treatment plan highlight our commitment to precision medicine. By seeking expert opinions and re-evaluating our approach, we ensure that our patients receive the most appropriate and effective treatments tailored to their unique health conditions. Through interventions like these, we aim to enhance patient outcomes and quality of life by adapting and responding to new medical insights as they arise. #Arbuda #ExpertConsultation #PathologyReview #CancerTreatment #RadiationTherapy